- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06824987
[Испытание устройства, которое не одобрено или очищено в США FDA] (APPRECIATE)
The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease (AMKD) who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes (G1 and G2). The primary hypothesis to be evaluated is that AZD2373, compared with placebo, will result in a greater reduction in UACR as assessed by the relative change from Baseline in UACR at Week 30.
Обзор исследования
Статус
Подробное описание
This is a Phase 2b study to assess efficacy and safety of AZD2373 involving 3 study treatment arms in Part A and 2 study treatment arms in Part B where participants and study personnel including study investigators are blinded to the assigned treatment.
Participants with 300 mg/g or greater UACR and eGFR ≥ 25mL/min/1.73m2 will be recruited into the study. Participants on kidney replacement therapy (dialysis or kidney transplant) or any other organ transplant will be excluded.
The study will have Part A and Part B. Part A (n = 96) will have a 1:1:1 randomization of participants to subgroups receiving weekly subcutaneous injections of 50 mg AZD2373, 150 mg AZD2373, and placebo. Part B (n = 40) will have a 4:1 randomization of participants to subgroups receiving every other week subcutaneous injections of 150 mg or placebo. Part B will begin after Part A is completely enrolled.
Both Part A and Part B will have same participant criteria and schedules. The SoA and visit schedule will not change for Part B.
All participants will remain in the study on treatment until the last participant has completed 30 weeks of treatment. The treatment duration will be up to minimum of 30 weeks of study treatment.
All participants will have the opportunity to enter the OLE study.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
Контакты и местонахождение
Места учебы
-
-
-
Birmingham, Соединенное Королевство, B15 2WB
- Research Site
-
Leicester, Соединенное Королевство, Le5 4PW
- Research Site
-
Liverpool, Соединенное Королевство, L22 0LG
- Research Site
-
London, Соединенное Королевство, SE1 9RT
- Research Site
-
London, Соединенное Королевство, NW3 2QG
- Research Site
-
London, Соединенное Королевство, SW17 0QT
- Research Site
-
London, Соединенное Королевство, SE5 8AZ
- Research Site
-
London, Соединенное Королевство, SM5 1AA
- Research Site
-
London, Соединенное Королевство, SW7 2AZ
- Research Site
-
Manchester, Соединенное Королевство, M13 9WL
- Research Site
-
-
-
-
Alabama
-
Alabaster, Alabama, Соединенные Штаты, 35007
- Research Site
-
Birmingham, Alabama, Соединенные Штаты, 35205
- Research Site
-
Irondale, Alabama, Соединенные Штаты, 35210
- Research Site
-
-
Arizona
-
Surprise, Arizona, Соединенные Штаты, 85374
- Research Site
-
-
California
-
Beverly Hills, California, Соединенные Штаты, 90211
- Research Site
-
Concord, California, Соединенные Штаты, 94520
- Research Site
-
Fremont, California, Соединенные Штаты, 94538
- Research Site
-
Gardena, California, Соединенные Штаты, 90247
- Research Site
-
Los Angeles, California, Соединенные Штаты, 90095
- Research Site
-
Valencia, California, Соединенные Штаты, 91355
- Research Site
-
-
Florida
-
Boca Raton, Florida, Соединенные Штаты, 33487
- Research Site
-
Brandon, Florida, Соединенные Штаты, 33511
- Research Site
-
Miami, Florida, Соединенные Штаты, 33126
- Research Site
-
Miami, Florida, Соединенные Штаты, 33173
- Research Site
-
Orlando, Florida, Соединенные Штаты, 32808
- Research Site
-
Pompano Beach, Florida, Соединенные Штаты, 33060
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Соединенные Штаты, 30322
- Research Site
-
Augusta, Georgia, Соединенные Штаты, 30912
- Research Site
-
Augusta, Georgia, Соединенные Штаты, 30909
- Research Site
-
Augusta, Georgia, Соединенные Штаты, 30904
- Research Site
-
Columbus, Georgia, Соединенные Штаты, 31904
- Research Site
-
Columbus, Georgia, Соединенные Штаты, 31901
- Research Site
-
Duluth, Georgia, Соединенные Штаты, 30096
- Research Site
-
Hinesville, Georgia, Соединенные Штаты, 31313
- Research Site
-
Lawrenceville, Georgia, Соединенные Штаты, 30046
- Research Site
-
Macon, Georgia, Соединенные Штаты, 31217
- Research Site
-
Macon, Georgia, Соединенные Штаты, 31210
- Research Site
-
Marietta, Georgia, Соединенные Штаты, 30067
- Research Site
-
Savannah, Georgia, Соединенные Штаты, 31406
- Research Site
-
Stockbridge, Georgia, Соединенные Штаты, 30281
- Research Site
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60612
- Research Site
-
Chicago, Illinois, Соединенные Штаты, 60643
- Research Site
-
Hinsdale, Illinois, Соединенные Штаты, 60521
- Research Site
-
Rockford, Illinois, Соединенные Штаты, 61107
- Research Site
-
-
Louisiana
-
Baton Rouge, Louisiana, Соединенные Штаты, 70808
- Research Site
-
Lafayette, Louisiana, Соединенные Штаты, 70508
- Research Site
-
New Orleans, Louisiana, Соединенные Штаты, 70112
- Research Site
-
Shreveport, Louisiana, Соединенные Штаты, 71103
- Research Site
-
-
Maryland
-
Bethesda, Maryland, Соединенные Штаты, 20889
- Research Site
-
Potomac, Maryland, Соединенные Штаты, 20854
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02114
- Research Site
-
Worcester, Massachusetts, Соединенные Штаты, 01608
- Research Site
-
-
Michigan
-
Lansing, Michigan, Соединенные Штаты, 48911
- Research Site
-
Roseville, Michigan, Соединенные Штаты, 48066
- Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, Соединенные Штаты, 55455
- Research Site
-
-
Mississippi
-
Columbus, Mississippi, Соединенные Штаты, 39705
- Research Site
-
Tupelo, Mississippi, Соединенные Штаты, 38801
- Research Site
-
-
New York
-
Brooklyn, New York, Соединенные Штаты, 11203
- Research Site
-
Brooklyn, New York, Соединенные Штаты, 11221
- Research Site
-
Laurelton, New York, Соединенные Штаты, 11413
- Research Site
-
New York, New York, Соединенные Штаты, 10010
- Research Site
-
Rockville Centre, New York, Соединенные Штаты, 11570
- Research Site
-
The Bronx, New York, Соединенные Штаты, 10461
- Research Site
-
-
North Carolina
-
Cary, North Carolina, Соединенные Штаты, 27511
- Research Site
-
Durham, North Carolina, Соединенные Штаты, 27705
- Research Site
-
Fayetteville, North Carolina, Соединенные Штаты, 28304
- Research Site
-
Gastonia, North Carolina, Соединенные Штаты, 28054
- Research Site
-
Greenville, North Carolina, Соединенные Штаты, 27834
- Research Site
-
Jacksonville, North Carolina, Соединенные Штаты, 28546
- Research Site
-
Kinston, North Carolina, Соединенные Штаты, 28501
- Research Site
-
Winston-Salem, North Carolina, Соединенные Штаты, 27103
- Research Site
-
Winston-Salem, North Carolina, Соединенные Штаты, 27157
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Соединенные Штаты, 45246
- Research Site
-
Columbus, Ohio, Соединенные Штаты, 43210
- Research Site
-
-
Pennsylvania
-
Bridgeville, Pennsylvania, Соединенные Штаты, 15017
- Research Site
-
Butler, Pennsylvania, Соединенные Штаты, 16001
- Research Site
-
Exton, Pennsylvania, Соединенные Штаты, 19341
- Research Site
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19104
- Research Site
-
-
South Carolina
-
Anderson, South Carolina, Соединенные Штаты, 29621
- Research Site
-
Columbia, South Carolina, Соединенные Штаты, 29203
- Research Site
-
Orangeburg, South Carolina, Соединенные Штаты, 29118
- Research Site
-
Spartanburg, South Carolina, Соединенные Штаты, 29306
- Research Site
-
-
Tennessee
-
Chattanooga, Tennessee, Соединенные Штаты, 37404
- Research Site
-
Nashville, Tennessee, Соединенные Штаты, 37232
- Research Site
-
-
Texas
-
Conroe, Texas, Соединенные Штаты, 77304
- Research Site
-
Conroe, Texas, Соединенные Штаты, 77384
- Research Site
-
Dallas, Texas, Соединенные Штаты, 75234
- Research Site
-
Dallas, Texas, Соединенные Штаты, 75235
- Research Site
-
Houston, Texas, Соединенные Штаты, 77054
- Research Site
-
Katy, Texas, Соединенные Штаты, 77450
- Research Site
-
Mesquite, Texas, Соединенные Штаты, 75149
- Research Site
-
Pearland, Texas, Соединенные Штаты, 77584
- Research Site
-
San Antonio, Texas, Соединенные Штаты, 78212
- Research Site
-
-
Virginia
-
Norfolk, Virginia, Соединенные Штаты, 23510
- Research Site
-
Portsmouth, Virginia, Соединенные Штаты, 23708
- Research Site
-
Richmond, Virginia, Соединенные Штаты, 23298
- Research Site
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Age: Male and female participants of African descent (including, but not limited to, Black, Black African, Black Caribbean, African American, Afro-Caribbean, Afro-Latino, West African, Mixed Black backgrounds, or other self-identified African diaspora heritage) aged 18 to 70 years, inclusive at the time of informed consent.
- Participants who have high-risk APOL1 genotype (G1/G1; G1/G2; G2/G2). The screening period can be extended if there are delays related to the shipment, handling, or processing of genotype results.
- A geometric mean UACR ≥ 300 mg/g calculated based on the mean of readings taken from 3 FMV urine samples collected on 3 consecutive days. Since the mean will be assessed for eligibility, any of the 3 readings may fall below 300 mg/g.
- eGFR ≥ 25 mL/min/1.73m2.
- Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
Exclusion Criteria:
-
Participants with diagnosis of Type 1 diabetes mellitus.
-
Body Mass Index > 45 kg/m2.
-
SBP > 180 mmHg/DBP > 110 mmHg (measured when the participant is considered to be at steady state, and preferably when they have taken their BP medications that same day).
-
QTcF > 470 ms, except participants with bundle branch block who should excluded if QTcF> 480 ms.
-
Acute coronary syndrome/Acute myocardial infraction with or without any coronary intervention within 6 months.
-
Transient ischaemic attack/ stroke within 3 months.
-
High grade (second to third) degree AV block or clinically significant sinus node dysfunction untreated with pacemaker.
-
A history of ventricular arrhythmias requiring treatment.
-
Participants with Type 2 diabetes mellitus must be excluded if ANY of the following conditions are present:
- Current or past use of insulin for more than 3 months and/or any maintenance therapy with insulin within 2 months of screening.
- Screening Haemoglobin A1c > 8.0%
- Receiving more than one anti-hyperglycaemic agent (excluding SGLT inhibitors and GLP-1 receptor agonists is permitted if prescribed for a purpose other than glycaemic control which can be taken in addition to one other anti-hyperglycaemic agent).
-
Participant on kidney replacement therapy (dialysis or kidney transplant) or any other organ transplant.
-
History or serologic evidence of autoimmune-mediated glomerular disease including but not limited to: lupus nephritis (positive lupus serology), ANCA associated vasculitis (antineutrophil cytoplasmic antibody), membranous nephropathy (anti-phospholipase A2 receptor antibody or other autoantibody associated with membranous nephropathy), anti-GBM disease (anti-GBM antibody), or IgA nephropathy.
-
Another underlying cause of kidney disease that is not associated with APOL1, including but not limited to polycystic kidney disease or, congenital anomalies of the kidney and urinary tract.
-
History of a diagnosed coagulopathy, a major unexplained bleeding event, or other high-risk bleeding diathesis.
-
A history of trypanosomiasis or leishmaniasis.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Четырехместный
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Плацебо Компаратор: Part A - Placebo group
Participants will be randomized at a 1:1:1 ratio to 3 study treatment arms. Participants will receive SC injection of the assigned dose. |
Accessorized Pre-Filled Syringe (Solution for injection). The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood. |
|
Экспериментальный: Part A - AZD2373 - Arm 1
Participants will be randomized at a 1:1:1 ratio to 3 study treatment arms. Participants will receive SC injection of the assigned dose. |
The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood. Accessorized Pre-Filled Syringe (Solution for injection) |
|
Экспериментальный: Part A - AZD2373 - Arm 2
Participants will be randomized at a 1:1:1 ratio to 3 study treatment arms. Participants will receive SC injection of the assigned dose. |
The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood. Accessorized Pre-Filled Syringe (Solution for injection) |
|
Экспериментальный: Part B - AZD2373 Arm 1
Participants will be randomized at a 4:1 ratio to 2 study treatment arms. Participants will receive SC injection of the assigned dose |
The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood. Accessorized Pre-Filled Syringe (Solution for injection) |
|
Плацебо Компаратор: Part B - Placebo group
Participants will be randomized at a 4:1 ratio to 2 study treatment arms. Participants will receive SC injection of the assigned dose |
Accessorized Pre-Filled Syringe (Solution for injection). The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Relative change in Urine Albumin-Creatinine Ratio (UACR)
Временное ограничение: From Baseline at Week 30
|
To assess the effect of AZD2373 versus placebo in reducing albuminuria |
From Baseline at Week 30
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Relative change in Urine Albumin-Creatinine Ratio (UACR)
Временное ограничение: From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
To assess the effect of AZD2373 versus placebo in reducing albuminuria |
From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
|
Relative change in Urine Protein-Creatinine Ratio (UPCR)
Временное ограничение: From Baseline at Week 30
|
To assess the effect of AZD2373 versus placebo in reducing proteinuria |
From Baseline at Week 30
|
|
Relative change in Urine Protein-Creatinine Ratio (UPCR)
Временное ограничение: From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
To assess the effect of AZD2373 versus placebo in reducing proteinuria |
From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
|
Proportion of participants achieving a 45% or greater reduction in Urine Albumin-Creatinine Ratio (UACR)
Временное ограничение: From Baseline at Week 30
|
To assess the proportion of participants achieving a 45% or greater Urine Albumin-Creatinine Ratio (UACR) reduction by treatment |
From Baseline at Week 30
|
|
Proportion of participants achieving a 45% or greater reduction in Urine Albumin-Creatinine Ratio (UACR)
Временное ограничение: From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
To assess the proportion of participants achieving a 45% or greater Urine Albumin-Creatinine Ratio (UACR) reduction by treatment |
From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
|
eGFR slope
Временное ограничение: From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
To assess pooled AZD2373 doses versus placebo on eGFR change |
From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
|
Incidence of development of ADA and ADA titer (if participants are ADA-positive)
Временное ограничение: During treatment (up to Week 30) and follow-up (up to 12 weeks)
|
To evaluate the immunogenicity of AZD2373 |
During treatment (up to Week 30) and follow-up (up to 12 weeks)
|
|
Plasma concentration
Временное ограничение: From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
To evaluate the PK of AZD2373 |
From Baseline at the End of Treatment (Until the last participant completes Week 30)
|
|
Adverse Events (AEs), Serious Adverse Events (SAEs), and Drug Adverse Events (DAEs).
Временное ограничение: From baseline at the End of Treatment (Until the last participant completes Week 30)
|
To assess the safety and tolerability of ranging doses of AZD2373. These events will be collected according to the timepoints specified in the schedule of assessments, starting from the time of signing the Informed Consent Form (ICF). |
From baseline at the End of Treatment (Until the last participant completes Week 30)
|
Соавторы и исследователи
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Другие идентификационные номера исследования
- D6800C00005
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Сроки обмена IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Критерии совместного доступа к IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org.
Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .